Immunome, Inc. $IMNM Shares Bought by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. increased its holdings in Immunome, Inc. (NASDAQ:IMNM) by 20.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 714,553 shares of the company’s stock after buying an additional 122,450 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Immunome were worth $15,349,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after buying an additional 1,144,788 shares during the period. Principal Financial Group Inc. increased its holdings in Immunome by 222.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after buying an additional 762,147 shares during the period. Polar Capital Holdings Plc increased its holdings in Immunome by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the company’s stock worth $12,398,000 after buying an additional 58,776 shares during the period. Candriam S.C.A. increased its holdings in Immunome by 170.2% in the 3rd quarter. Candriam S.C.A. now owns 859,527 shares of the company’s stock worth $10,065,000 after buying an additional 541,441 shares during the period. Finally, TD Asset Management Inc increased its holdings in Immunome by 15.8% in the 3rd quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock worth $8,212,000 after buying an additional 95,750 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insiders Place Their Bets

In other Immunome news, CFO Max Rosett sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer owned 54,037 shares in the company, valued at approximately $1,184,491.04. This represents a 54.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at approximately $476,080. This represents a 30.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IMNM shares. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Stephens cut their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a report on Thursday, January 15th. Finally, Truist Financial upgraded shares of Immunome to a “strong-buy” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Immunome Trading Up 1.1%

Immunome stock opened at $22.44 on Friday. Immunome, Inc. has a 12 month low of $7.39 and a 12 month high of $27.65. The stock’s 50 day simple moving average is $21.94 and its two-hundred day simple moving average is $20.97. The firm has a market cap of $2.54 billion, a PE ratio of -9.27 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, equities research analysts forecast that Immunome, Inc. will post -2.5 EPS for the current year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.